Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €97.97 EUR
Change Today +0.20 / 0.20%
Volume 3.0M
SAN On Other Exchanges
EN Paris
EN Paris
New York
As of 11:39 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

sanofi (SAN) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/20/15 - €99.83
52 Week Low
10/29/14 - €69.58
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SANOFI (SAN)

sanofi (SAN) Details

Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, including Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, as well as Toujeo, an insulin glargine. The company also offers Cerezyme to treat gaucher disease; Myozyme/Lumizyme for the pompe disease treatment; Fabrazyme for fabry disease treatment; and Aldurazyme to treat mucopolysaccharidosis type I, as well as provides Aubagio and Lemtrada for multiple sclerosis. In addition, it provides Jevtana for prostate cancer; Taxotere for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers; Thymoglobulin to treat acute rejection in organ transplantation, aplastic anemia, and graft-versus-host diseases; Eloxatin for colorectal cancer; Mozobil for treating hematologic malignancies; and Zaltrap for oxaliplatin resistant metastatic colorectal cancer. Further, the company offers other prescription drugs, such as Plavix for atherothrombosis and acute coronary syndrome; Lovenox for the treatment and prevention of deep vein thrombosis and acute coronary syndromes; Aprovel/CoAprovel for hypertension; Renagel/Renvela to treat chronic kidney disease; Depakine for epilepsy; Synvisc/Synvisc-One for the treatment of pain associated with osteoarthritis of the knee; Stilnox/Ambien/Myslee to treat sleep disorders; Multaq for atrial fibrillation; Allegra for the treatment of allergic rhinitis and urticarial; Actonel for osteoporosis and paget's disease; and Auvi-Q/Allerject for the treatment of severe allergic reactions. Additionally, it offers consumer health care products and generic medicines; and vaccine and animal health products. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

113,496 Employees
Last Reported Date: 03/11/15
Founded in 1973

sanofi (SAN) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

sanofi (SAN) Key Developments

Sanofi Reports Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Reports Impairment Charges for the Second Quarter Ended June 30, 2015; Provides Earnings Guidance for the Year 2015

Sanofi reported consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net sales of EUR 9,378 million against EUR 8,075 million a year ago. Operating income was EUR 1,995 million against EUR 1,246 million a year ago. Net income attributable to equity holders of the company was EUR 1,302 million or EUR 1.00 per share against EUR 777 million or EUR 0.59 per share a year ago. Income before tax and associates and joint ventures was EUR 1,883 million against EUR 1,152 million a year ago. For the six months, the company reported net sales of EUR 18,188 million against EUR 15,917 million a year ago. Operating income was EUR 3,398 million against EUR 2,674 million a year ago. Income before tax and associates and joint ventures was EUR 3,189 million against EUR 2,539 million a year ago. Net income attributable to equity holders of the company was EUR 2,325 million or EUR 1.78 per share against EUR 1,861 million or EUR 1.41 per share a year ago. Acquisitions of property, plant and equipment and software were EUR 667 million against EUR 529 million for the same period last year. Free cash flow was EUR 3,084 million against EUR 2,390 million a year ago. Net debt was increased from EUR 7,171 million at December 31, 2014 to EUR 9,726 million at June 30, 2015 (amount net of EUR 4,701 million cash and cash equivalents) and included the translation impact of the debt, which represented EUR 391 million, mainly related to the debt held in U.S. dollars. For the quarter, the company reported impairment of intangible assets of EUR 1 million against EUR 71 million a year ago. The company expected 2015 business EPS to be stable to slightly growing versus 2014 at constant average exchange rates, barring major unforeseen adverse events In addition, the positive currency impact on 2015 full-year business EPS is estimated to be approximately +10%, under the assumption that exchange rates remain stable in the following two quarters at the average rates of June 2015.

Sanofi Mulls Acquisitions

Sanofi (ENXTPA:SAN) is looking for acquisitions. Chief Executive Officer, Olivier Brandicourt said, “Sanofi has a strong balance sheet which allows the group to potentially tap into M&A opportunities to further boost its growth profile.”

Sanofi's First LixiLan Phase III Study Met Primary Endpoint

Sanofi announced that the LixiLan-O Phase III clinical trial met its primary objective in patients with type 2 diabetes treated with metformin. The fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide, a GLP-1 RA, demonstrated statistically superior reduction in HbA1c (average blood glucose over the previous three months) compared with lixisenatide and compared with insulin glargine 100 units/mL. Overall, the fixed-ratio combination had a safety profile reflecting those of lixisenatide and insulin glargine 100 units/mL. The Phase III LixiLan clinical development program began in first quarter of 2014 and consists of the LixiLan-O and LixiLan-L trials. LixiLan-O investigated the efficacy and safety of a once-daily single injection of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide versus treatment with either lixisenatide or insulin glargine 100 units/mL over a 30 week period in 1,170 patients whose type 2 diabetes was not adequately controlled on metformin alone or on metformin combined with a second oral anti-diabetic agent. Treatment with metformin was continued for all participants throughout the study. Full results will be communicated in an appropriate scientific forum. The ongoing LixiLan-L study investigates the efficacy and safety of a once-daily single injection of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide versus treatment with insulin glargine 100 units/mL over a 30-week period in 736 patients whose type 2 diabetes was not adequately controlled at screening on a basal insulin with or without oral anti-diabetic drugs. Only metformin, if taken, was continued throughout the study. The study will be completed in third quarter of 2015. Following an analysis of results from both Phase III studies, LixiLan-O and LixiLan-L, Sanofi will determine the next steps in the regulatory process. Currently, regulatory submissions are planned for fourth quarter of 2015 in the United States and first quarter of 2016 in the European Union.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SAN:FP €97.97 EUR +0.20

SAN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $70.01 USD -0.15
Amgen Inc $176.59 USD +4.90
Bayer AG €134.05 EUR +0.176
Medtronic PLC $78.39 USD +0.11
Novo Nordisk A/S kr398.40 DKK +1.20
View Industry Companies

Industry Analysis


Industry Average

Valuation SAN Industry Range
Price/Earnings 26.4x
Price/Sales 3.5x
Price/Book 2.2x
Price/Cash Flow 17.4x
TEV/Sales 2.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at